Johnson & Johnson ($JNJ) pessimists are already worried that Olysio will end up like a mayfly, with a short, happy, busy life and an all-too-sudden end. If the U.K.'s cost-effectiveness gatekeepers offer any sign of Olysio's future, their worries may be well-founded. Report